Fig. 1

a KM curves for persistence with infliximab and intravenous golimumab. Note: non-persistence defined as a gap > 10 weeks in therapy. b KM curve for the composite outcome of persistence or dose escalation of infliximab and intravenous golimumab. Note: non-persistence defined as a gap > 10 weeks in therapy